Biodesix (NASDAQ:BDSX) Releases Earnings Results, Beats Expectations By $0.01 EPS

Biodesix (NASDAQ:BDSX) released its quarterly earnings data on Friday. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01, RTT News reports. Biodesix had a negative net margin of 73.08% and a negative return on equity of 505.95%. The company had revenue of $18.15 million during the quarter, compared to the consensus estimate of $18.45 million. During the same period last year, the firm earned ($0.12) EPS. Biodesix updated its FY 2024 guidance to EPS.

Biodesix Price Performance

Shares of NASDAQ BDSX traded down $0.40 during mid-day trading on Friday, reaching $1.30. 556,069 shares of the company were exchanged, compared to its average volume of 149,748. The stock has a market capitalization of $188.73 million, a PE ratio of -2.83 and a beta of 1.22. The company has a quick ratio of 3.28, a current ratio of 3.28 and a debt-to-equity ratio of 0.99. Biodesix has a 52 week low of $1.15 and a 52 week high of $2.21. The company’s 50 day moving average price is $1.72 and its 200 day moving average price is $1.60.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Craig Hallum initiated coverage on shares of Biodesix in a research report on Friday, July 26th. They issued a “buy” rating and a $3.00 price objective for the company. Scotiabank began coverage on shares of Biodesix in a report on Monday, September 16th. They issued a “sector outperform” rating and a $3.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $3.06.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.